Quantum Biopharma licensee Unbuzzd to host webinar

Mr. Zeeshan Saeed reports QUANTUM BIOPHARMA LICENSEE UNBUZZD WELLNESS TO HOST LIVE WEBINAR FOR ITS DISRUPTIVE BEVERAGE INNOVATION THAT SPEEDS ALCOHOL METABOLISM, REDUCES SYMPTOMS OF INTOXICATION Quantum Biopharma Ltd.'s licensee, Unbuzzd Wellness Inc., the company behind unbuzzd -- the scientifically proved and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms -- as part of its Regulation D 506(c) offering and up to $5-million raise, will host an investor webinar on Thursday, Oct. 30, 2025, at 4:15 p.m. EST (1:15 p.m. PST). The shareholders of Quantum Biopharma will not be diluted by this offering. During the webinar, Unbuzzd chief executive officer John Duffy, adviser Jason Sawyer, medical director Dr. Eric Hoskins and board co-chair Gerry David, former CEO of Celsius, will discuss the current investment opportunity for its scientifically backed beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms. Investors will also learn about the company leadership and their path to scale distribution and retail sales. A question-and-answer session will follow the presentation. Unbuzzd investor webinar Date:  Thursday, Oct. 30, 2025 Time:  4:15 p.m. EST (1:15 p.m. PST) Register for the webinar. Mr. Duffy stated: "We invite potential investors to discuss our Regulation D 506(c) offering, targeting $5.0-million (U.S.) to expand unbuzzd direct-to-consumer, distributor and retail channel availability and work toward a possible IPO. Unbuzzd has the potential to be one of the most impactful new products of 2026 due to the meaningful innovation, functionality, relevance and backing by clinical research. The brand has responded directly to emerging needs by connecting with consumers' lifestyles and values." A replay of the webinar will be available upon request by contacting [email protected] or 518-862-5993. This Unbuzzd Reg D 506(c) offering is for accredited investors only. Quantum Biopharma shareholders will not be diluted by this offering. About Quantum Biopharma Ltd. Quantum Biopharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum Biopharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum Biopharma invented Unbuzzd and spun out its over-the-counter version to a company, Celly Nutrition Corp., now Unbuzzd Wellness, led by industry veterans. Quantum Biopharma retains ownership of 20.10 per cent (as of June 30, 2025) of Unbuzzd Wellness. The agreement with Unbuzzd Wellness also includes royalty payments of 7 per cent of sales from Unbuzzd until payments to Quantum Biopharma total $250-million. Once $250-million is reached, the royalty drops to 3 per cent in perpetuity. Quantum Biopharma retains 100 per cent of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum Biopharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. We seek Safe Harbor.